Products with Anticancer bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5770 | 4'-Hydroxywogonin |
| 4'-Hydroxywogonin has positive effect on inhabiting those human tumor lines in vitro, with IC50 value is 8.3-38.4ug/mL . | |
| BCN5781 | Isofuranodiene |
| 1. Isofuranodiene has anticancer activity, by inhibiting the proliferation and inducing apoptosis in cancer cells. 2. Isofuranodiene protects GalN/LPS-induced liver injury in SD rats, it may be a potential functional food ingredient for the prevention and treatment of liver diseases. 3. Isofuranodiene can induce apoptosis in colon cancer cells in a time and concentration-dependent manner suggesting a potential role as models for the development of chemopreventive agents. 4. Isofuranodiene at concentrations of 25 and 12.5 lM alone, or in combination with 50 nM nerve growth factor (NGF) , shows a marked stimulation of neuritogenesis,which appears to be a promising neurotrophic and neuroprotective agent. | |
| BCN5782 | (3beta,24xi)-Cycloartane-3,24,25-triol |
| 1. Cycloartane-3,24,25-triol has potential for development as an anti-cancer agent against prostate cancer. 2. Cycloartane-3,24,25-triol reduces the viability of PC-3 and DU145 cell lines with IC50 values of 2.226 ± 0.28 μM and 1.67 ± 0.18 μM respectively. | |
| BCN5784 | Norcepharadione B |
| Norcepharadione B shows good inhibitory activity against the replication of HSV-1, it also shows antimalarial activity with EC50 values of 7.5mug/ml. Norcepharadione B exhibits significant cytotoxicity against five human tumor cell lines (A-549, SK-OV-3, SK-MEL-2, XF-498 and HCT-15) in vitro. Norcepharadione B shows significant inhibitory effects on both ADP-induced and thrombin-induced platelet aggregation. | |
| BCN5789 | Matairesinol |
| Matairesinol has radical and superoxide scavenging activities,; it also has anti-angiogenic activity by suppressing mROS signaling , can decrease hypoxia-inducible factor-1α in hypoxic HeLa cells.Matairesinol has anti-osteoporotic activity via p38/ERK-NFATc1 signaling, but not by way of anti-resorptive action. Matairesinol could markedly benefit TRAIL-based tumor therapies, including those aimed at prostate cancer. | |
